Skip to main content

Moleculin Biotech Inc

For the period ended Jun 30, 2024. Filed Aug 13, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 13, 2024

MBRX$8.70-0.3%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Table of Contents

Form 10-Q

Table of Contents

Page
PART I – FINANCIAL INFORMATION3
Item 1.Financial Statements (Unaudited)3
Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 20233
Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months ended June 30, 2024 and 20234
Condensed Consolidated Statements of Cash Flows for the Six Months ended June 30, 2024 and 20235
Condensed Consolidated Statements of Stockholders' Equity for the Six Months Ended June 30, 2024 and 20236
Notes to Condensed Consolidated Financial Statements7
Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations13
Item 3.Quantitative and Qualitative Disclosures About Market Risk19
Item 4.Controls and Procedures19
PART II – OTHER INFORMATION20
Item 1.Legal Proceedings20
Item 1A.Risk Factors20
Item 2.Unregistered sales of Equity Securities and Uses of Proceeds20
Item 3.Defaults Upon Senior Securities20
Item 4.Mine Safety Disclosures20
Item 5.Other Information20
Item 6.Exhibits21
Signatures22
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.